| Name | Date Acquired | How Acquired | Date Sold | Purchaser Name | Gross Sales Price | Basis | Basis Method | Sales Expenses | Total (net) | Accumulated Depreciation |
|---|---|---|---|---|---|---|---|---|---|---|
| VIROPHARMA | 2013-12 | Purchased | 2013-12 | 2,467 | 2,489 | -22 | ||||
| WELLS FARGO LONG TERM | 2010-12 | Purchased | 2013-12 | 5,992 | 6,181 | -189 |
| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| WELLS FARGO ASSET ALLOCATION | 3,299 | 4,782 |
| NATIXIS FDS | 4,567 | 4,671 |
| PIMCO ALL ASSET | 4,600 | 4,462 |
| PIMCO UNCONSTRAINED | 7,347 | 7,349 |
| IVY FUNDS INC | 3,975 | 5,220 |
| BLACKROCK GLOBAL | 4,453 | 4,891 |
| Description | Revenue And Expenses Per Books | Net Investment Income | Adjusted Net Income |
|---|---|---|---|
| CAPITAL GAIN DISTRIBUTION | 160 |
| Description | Amount |
|---|---|
| CURRENT YEAR ADJUSTMENT | 29 |